This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Therapix Biosciences Ltd.
Drug Names(s): THXRS01, THX RS01, PEA (Palmitoylethanolamide) + THC (Tetrahydrocannabinol), PEA + THC
Description: THX-RS01 was developed based on entourage technology (the entourage effect). The drug combines a synthetic cannabinoid mimetic of PEA (palmitoylethanolamide) with THC.
Therapix and Dekel
In January 2015, Therapix entered into a binding Term Sheet outlining a licensing and royalty agreement with Dekel Pharmaceuticals, a company focused on the development of drugs where a lower effective dose-response can be achieved via the entourage effect to treat chronic pain and inflammation. Under the agreement, Dekel has granted Therapix the exclusive worldwide right to develop, manufacture and commercialize combination drug therapies based on Dekel's proprietary technology.
In exchange for granting of this right to Therapix, Dekel will receive an upfront license fee, cash or equity payments based on the achievement of specific development milestones, and a time-limited option to purchase Therapix common stock. Additionally, Dekel will receive a royalty based on a percentage of net revenues from the sale of products developed under the license, or fees received by Therapix for any potential sublicense or assignment of the license. The...See full deal structure in Biomedtracker
Additional information available to subscribers only: